How Research Peptides Are Synthesized: Solid-Phase Peptide Synthesis Explained

Introduction

The question of how peptides are made has a well-documented answer in the chemical literature. Short and medium-length research peptides are produced almost universally by solid-phase peptide synthesis (SPPS), the stepwise chemical method introduced by Robert Bruce Merrifield in 1963 [1]. Longer chains and folded proteins are more often produced by recombinant expression in living cells. This article describes both routes at a textbook level: the solid-phase concept, the protecting-group chemistries known as Boc and Fmoc, resins and linkers, coupling reagents, cleavage, purification by preparative reversed-phase HPLC, lyophilization and analytical confirmation. It is a description of published chemistry, not a procedure, and it makes no claims about the properties or effects of any compound.

A peptide is a chain of amino acids joined by amide bonds, written from the amino terminus (N-terminus) to the carboxyl terminus (C-terminus); the library's overview of what peptides are covers that background. Forming each amide bond requires activating one carboxyl group while keeping every other reactive group from participating, and most of peptide synthesis is the management of that selectivity problem.

Merrifield and the solid-phase concept

Before 1963, peptides were assembled in solution, with each intermediate isolated and purified before the next residue was added. Merrifield's insight was to anchor the C-terminal amino acid covalently to an insoluble polystyrene bead and to grow the chain while it remained attached [1]. Because the product is bound to a solid, every excess reagent and soluble by-product can be removed by simple filtration and washing rather than by extraction or crystallization. The cycle of deprotection, washing, coupling and washing is repeated once per residue, and the finished chain is released from the support only at the end.

Merrifield described the method's rationale and development in his 1986 Nobel lecture, published in Science [2]; he had received the 1984 Nobel Prize in Chemistry "for his development of methodology for chemical synthesis on a solid matrix" [3]. The approach made automated synthesizers possible and remains the foundation of research-peptide manufacturing [4].

Protecting-group chemistry: Boc and Fmoc

Each incoming amino acid carries a temporary protecting group on its alpha-amino nitrogen so that it cannot react with itself or with the activated carboxyl group of another monomer. After coupling, that group is removed to expose the new N-terminus for the next cycle. Reactive side chains (for example those of lysine, aspartate, cysteine and arginine) carry semi-permanent protecting groups that survive every cycle and are removed only at the end. The two dominant strategies are named for their temporary alpha-amino protecting groups.

Boc chemistry

Merrifield's original work used the tert-butyloxycarbonyl (Boc) group, which is removed by moderate acid such as trifluoroacetic acid (TFA) at each cycle. Because the side-chain groups must survive repeated acid exposure, they are chosen to require a stronger acid, and final cleavage in the classical Boc scheme uses anhydrous hydrogen fluoride [2, 4]. The chemistry remains in use for certain difficult sequences, but hydrogen fluoride requires specialized apparatus.

Fmoc chemistry

Carpino and Han introduced the 9-fluorenylmethoxycarbonyl (Fmoc) group as a base-labile amino-protecting group, describing its properties in the Journal of Organic Chemistry in 1972 [5]. Fmoc is removed by a mild base, conventionally a secondary amine such as piperidine, while acid-labile side-chain protecting groups (tert-butyl-based groups and their relatives) remain intact. This orthogonality means the final cleavage can be carried out with TFA rather than hydrogen fluoride. Behrendt, White and Offer reviewed the state of Fmoc solid-phase synthesis in the Journal of Peptide Science in 2016 and noted that Fmoc/tBu chemistry had become the default for the great majority of laboratory and commercial synthesis [6]. Amblard and colleagues provided a comparable methods overview in Molecular Biotechnology in 2006 [4].

Resins and linkers

The solid support is typically a cross-linked polystyrene bead, sometimes grafted with polyethylene glycol. The bead does not bind the peptide directly; a linker sits between the two, and its chemistry determines the C-terminus of the released peptide [4, 6]. A Wang-type linker releases a C-terminal carboxylic acid on acid cleavage. A Rink amide linker releases a C-terminal amide, which is the terminus found in many bioactive peptides, including the decapeptide kisspeptin-10 and the nonapeptide oxytocin. Chlorotrityl linkers release the peptide under very mild acid with side-chain protection intact, which is used when a protected fragment is needed for later assembly.

Coupling reagents and chain assembly

Forming an amide bond between a free amine and a carboxylic acid does not proceed spontaneously under practical conditions. A coupling reagent activates the carboxyl group so that the amine can attack it. The earliest reagents were carbodiimides, notably N,N'-dicyclohexylcarbodiimide (DCC) and its more soluble relative N,N'-diisopropylcarbodiimide (DIC), often used with an additive such as 1-hydroxybenzotriazole (HOBt) or ethyl cyanohydroxyiminoacetate (Oxyma) to limit racemization at the activated residue. Later generations include aminium and uronium salts such as HBTU and HATU and phosphonium salts such as PyBOP. El-Faham and Albericio surveyed this reagent landscape in a 2011 Chemical Reviews article whose title, "peptide coupling reagents, more than a letter soup," captures the field's vocabulary problem [7].

Each coupling uses an excess of activated amino acid so that as many chains on the resin as possible are extended. Chains that fail to couple at a given step carry a deletion of that residue through to the end, which is the origin of the deletion-sequence impurities that purification must later remove [4, 6].

Cleavage and global deprotection

When the sequence is complete, the peptide is released from the resin and the side-chain protecting groups are removed in a single acid treatment. In Fmoc chemistry this is done with TFA in the presence of scavengers, small molecules such as water or triisopropylsilane that trap the reactive carbocations generated as protecting groups depart, preventing them from alkylating sensitive residues such as tryptophan and methionine [4, 6]. For cysteine-containing sequences such as oxytocin, formation of the disulfide bridge is an additional step carried out in solution after cleavage.

Purification by preparative RP-HPLC

Crude peptide at this stage is a mixture of the target sequence, deletion and truncation products, incompletely deprotected chains, oxidized variants and scavenger adducts. Preparative reversed-phase high-performance liquid chromatography (RP-HPLC) is the standard purification method. The mixture is loaded onto a hydrophobic stationary phase and eluted with a gradient of increasing organic solvent, usually acetonitrile in water with a small amount of TFA as an ion-pairing agent; components separate by hydrophobicity and are collected as fractions [8, 9]. Andersson and colleagues described the pairing of SPPS with preparative RP-HPLC as the established production route for peptides at research and manufacturing scale [8]. De Luca and colleagues reviewed the downstream processing of peptides by preparative liquid chromatography in 2021 [9].

Fractions meeting the purity specification are pooled. Because the eluent contains TFA, the purified peptide is usually obtained as a trifluoroacetate salt; a counter-ion exchange step can convert it to an acetate salt where that is the intended presentation.

Lyophilization

The pooled fractions are frozen and the solvent is removed by sublimation under reduced pressure, a process called lyophilization or freeze-drying. Wang's 2000 review in the International Journal of Pharmaceutics describes the physical basis of the method and its rationale for peptides and proteins: removing water reduces the molecular mobility and the water availability on which hydrolytic degradation pathways depend, so the dried solid is more stable in storage than the solution [10]. The product is a porous solid cake or powder. The library's article on why peptides are lyophilized treats the physical chemistry in detail.

Identity and purity confirmation by LC-MS

The final step is analytical. Analytical RP-HPLC reports purity as the area of the main peak relative to all detected peaks under the stated method [11]. Mass spectrometry, by electrospray ionization or MALDI, measures the molecular mass of the principal component and compares it with the value calculated from the intended sequence [12]. Coupled LC-MS does both in one run and can flag sequence variants that a UV trace alone would not distinguish; Lian and colleagues reviewed its application to synthetic peptides in 2021 [13]. These results are what populate a certificate of analysis, and the library's explainer on certificates of analysis and third-party testing describes how such documents are read.

Recombinant expression for longer peptides and proteins

Chemical synthesis has a length ceiling in practice. If each coupling proceeds at a very high but finite efficiency, the cumulative yield of full-length product falls with every additional residue, and the burden on purification rises accordingly. Karas, Wade and Hossain illustrated the point in a 2021 Chemical Reviews account of the chemical synthesis of insulin, a 51-residue, two-chain, three-disulfide molecule that remained a synthetic challenge for decades [14]. Beyond a few dozen residues, and for any sequence that must fold with correctly paired disulfides, recombinant expression is generally the preferred route.

In recombinant production, DNA encoding the peptide or protein is introduced into a host organism, most commonly Escherichia coli, which transcribes and translates it. The product is then recovered from the cells, refolded where necessary and purified by chromatography. Rosano and Ceccarelli reviewed the advances and remaining challenges of E. coli expression in 2014 [15]. The 83-residue analog IGF-1 LR3, which contains three disulfide bonds, is an example of a research material produced this way. The FDA-approved drug mecasermin (Increlex), a recombinant human IGF-1, is produced in E. coli according to its prescribing information, which is cited here as a regulatory record of the manufacturing route only [16].

The two routes are complementary. Chemical SPPS offers precise control over sequence, including unnatural amino acids that a ribosome cannot install; recombinant expression offers economical access to long, folded chains. Both converge on the same downstream steps of chromatographic purification, lyophilization and LC-MS characterization.

Regulatory framing

The chemistry described above is the same whether the product is destined for an approved pharmaceutical or a research laboratory; what differs is the regulatory framework under which it is made and sold. Research peptides supplied under research-use-only terms are laboratory reference materials, not approved drugs or products for human consumption. Nothing in this article describes conditions, quantities or procedures for producing any material for human use.

Summary

Research peptides are synthesized by solid-phase peptide synthesis: the C-terminal residue is anchored to a resin through a linker, protected amino acids are coupled one at a time with activating reagents, the temporary Fmoc or Boc group is removed between cycles, and the finished chain is cleaved and deprotected with acid. The crude product is purified by preparative RP-HPLC, lyophilized and characterized by analytical HPLC and mass spectrometry. Long or disulfide-rich sequences are more often produced by recombinant expression in a host such as E. coli. Merrifield's 1963 method and Carpino and Han's 1972 Fmoc group between them account for most synthetic peptides in the published literature.

References

1. Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963;85(14):2149-2154. doi:10.1021/ja00897a025
2. Merrifield B. Solid phase synthesis. Science. 1986;232(4748):341-347. PMID: 3961484 (doi:10.1126/science.3961484)
3. The Nobel Prize in Chemistry 1984. NobelPrize.org. Nobel Prize Outreach. Source: nobelprize.org
4. Amblard M, Fehrentz JA, Martinez J, Subra G. Methods and protocols of modern solid phase peptide synthesis. Mol Biotechnol. 2006;33(3):239-254. PMID: 16946453 (doi:10.1385/MB:33:3:239)
5. Carpino LA, Han GY. 9-Fluorenylmethoxycarbonyl amino-protecting group. J Org Chem. 1972;37(22):3404-3409. doi:10.1021/jo00795a005
6. Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. J Pept Sci. 2016;22(1):4-27. PMID: 26785684 (doi:10.1002/psc.2836)
7. El-Faham A, Albericio F. Peptide coupling reagents, more than a letter soup. Chem Rev. 2011;111(11):6557-6602. PMID: 21866984 (doi:10.1021/cr100048w)
8. Andersson L, Blomberg L, Flegel M, Lepsa L, Nilsson B, Verlander M. Large-scale synthesis of peptides. Biopolymers. 2000;55(3):227-250. PMID: 11074417 (doi:10.1002/1097-0282(2000)55:3<227::AID-BIP50>3.0.CO;2-7)
9. De Luca C, Lievore G, Bozza D, Buratti A, Cavazzini A, Ricci A, et al. Downstream processing of therapeutic peptides by means of preparative liquid chromatography. Molecules. 2021;26(15):4688. PMID: 34361839 (doi:10.3390/molecules26154688)
10. Wang W. Lyophilization and development of solid protein pharmaceuticals. Int J Pharm. 2000;203(1-2):1-60. PMID: 10967427 (doi:10.1016/S0378-5173(00)00423-3)
11. Moffatt F, Senkans P, Ricketts D. Approaches towards the quantitative analysis of peptides and proteins by reversed-phase high-performance liquid chromatography in the absence of a pure reference sample. J Chromatogr A. 2000;891(2):235-242. PMID: 11043783 (doi:10.1016/s0021-9673(00)00620-8)
12. Strupat K. Molecular weight determination of peptides and proteins by ESI and MALDI. Methods Enzymol. 2005;405:1-36. PMID: 16413308 (doi:10.1016/S0076-6879(05)05001-9)
13. Lian Z, Wang N, Tian Y, Huang L. Characterization of synthetic peptide therapeutics using liquid chromatography-mass spectrometry: challenges, solutions, pitfalls, and future perspectives. J Am Soc Mass Spectrom. 2021;32(8):1852-1860. PMID: 34110145 (doi:10.1021/jasms.0c00479)
14. Karas JA, Wade JD, Hossain MA. The chemical synthesis of insulin: an enduring challenge. Chem Rev. 2021;121(8):4531-4560. PMID: 33689304 (doi:10.1021/acs.chemrev.0c01251)
15. Rosano GL, Ceccarelli EA. Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol. 2014;5:172. PMID: 24860555 (doi:10.3389/fmicb.2014.00172)
16. US Food and Drug Administration. Increlex (mecasermin) injection: prescribing information. NDA 021839. Source: accessdata.fda.gov